Amicus Therapeutics, Inc. (FOLD) to Release Earnings on Monday
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is set to post its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Amicus Therapeutics to post earnings of ($0.37) per share for the quarter.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the prior year, the company earned ($0.40) earnings per share. On average, analysts expect Amicus Therapeutics to post $-1.31 EPS for the current fiscal year and $-0.99 EPS for the next fiscal year.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at 14.03 on Monday. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a 50 day moving average of $14.34 and a 200-day moving average of $11.33. The firm’s market cap is $2.31 billion.
FOLD has been the subject of a number of analyst reports. Cowen and Company reissued a “buy” rating and set a $16.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Robert W. Baird lifted their price objective on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. BidaskClub raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $15.00 price objective (up from $13.00) on shares of Amicus Therapeutics in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and an average target price of $17.81.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/amicus-therapeutics-inc-fold-to-release-earnings-on-monday.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.